Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LNCB 74 (Primary)
  • Indications Biliary cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors NextCure

Most Recent Events

  • 01 May 2025 According to a NextCure media release, company plans to provide a proof of concept data readout in the first half of 2026.
  • 01 May 2025 According to a NextCure media release, LNCB74 antibody-drug conjugate program completing cohort 2 in April 2025. Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and company expect to be in a position to initiate backfill cohorts in the second half of the year with 10 active investigator sites, and an additional 3 sites projected to be onboard in May 2025.
  • 06 Mar 2025 According to a NextCure media release, cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers completed in February 2025 and company is planning to initiate backfill cohorts in the second half of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top